Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 1.00 |
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | DPYD | Q12882 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL8235 | 1.00 | — | — | |
| Uracil SCHEMBL11607890 | 1.00 | — | — | |
| Uracil SCHEMBL5089507 | 1.00 | — | — | |
| Uracil SCHEMBL710130 | 0.97 | — | — | |
| Uracil SCHEMBL2161716 | 0.97 | — | — | |
| Uracil SCHEMBL18010636 | 0.97 | — | — | |
| Uracil SCHEMBL16116311 | 0.97 | — | — | |
| Uracil SCHEMBL4664232 | 0.97 | CRBN (0.94) | CRBNMMP2TP53TYMPGSK3B | |
| Uracil SCHEMBL21385227 | 0.97 | — | — | |
| Uracil SCHEMBL8767625 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114106125-B | Ginkgo peptide, special medical formula food containing ginkgo peptide and application of ginkgo peptide | 大连海洋大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-114106125-A | Ginkgo peptide, special medical formula food containing same and application thereof | 大连海洋大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-111778362-A | Novel freeze-dried nucleic acid detection kit and detection method for coronavirus, influenza virus and pneumonia virus | 深圳容金科技有限公司 | 2020-10-16 | — | — | CN | disclosed |
| CN-108079982-B | Modified silica gel filler, preparation method and application | 苏州纳微科技股份有限公司 | 2020-03-13 | — | — | CN | disclosed |
| CN-110290794-A | The microRNA and its purposes in cancer treatment of 5- halo uracil modification | 纽约州州立大学研究基金会 | 2019-09-27 | — | — | CN | disclosed |
| CN-110195037-A | A kind of human umblilical vein endothelial primary separation and culture method | 西安交通大学 | 2019-09-03 | — | — | CN | disclosed |
| US-20190214145-A1 | Method and systems for creating and screening patient metabolite profile to diagnose current medical condition, diagnose current treatment state and recommend new treatment regimen | KUREK ITZHAK (US) | 2019-07-11 | — | — | US | disclosed |
| CN-109827985-A | It is a kind of based on NMR metabolism group to the discrimination method of maca different cultivars | 长春中医药大学 | 2019-05-31 | — | — | CN | disclosed |
| CN-109390037-A | The full site recognition methods of mature miRNA based on SVM-AdaBoost | 齐齐哈尔大学 | 2019-02-26 | — | — | CN | disclosed |
| EP-3390324-A1 | FERTILIZER COMPOSITIONS FOR PLANTS AND SOILS | Envirokure Incorporated (US) | 2018-10-24 | — | — | EP | disclosed |
| CN-101496774-A | Cosmetic composition comprising ascorbic acid 2-glucoside and ergothioneine | LVMH RECH (FR) | 2009-08-05 | — | — | CN | disclosed |
| US-7557175-B2 | Poly(carbonate-co-urea) copolymers and melt transesterification method of preparing these copolymers | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2009-07-07 | — | — | US | disclosed |
| US-20090142285-A1 | COSMETIC COMPOSITION COMPRISING ASCORBIC ACID 2-GLUCOSIDE AND ERGOTHIONEINE | LVMH RECHERCHE | 2009-06-04 | — | — | US | disclosed |
| US-20080233164-A1 | Polymer for Use in Conduits, Medical Devices and Biomedical Surface Modification | UCL BIOMEDICAL PLC (GB) | 2008-09-25 | — | — | US | disclosed |
| CN-1324034-C | Dioxazole pyrimidine nucleotide compounds with function of releasing NO and its use in pharmaceutics | CHINESE PHARMACEUTICAL UNIV (CN) | 2007-07-04 | — | — | CN | disclosed |
| EP-0491793-B1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RES INST (US) | 2005-11-30 | — | — | EP | disclosed |
| CN-1583753-A | Dioxazole pyrimidine nucleotide compounds with function of releasing NO and its use in pharmaceutics | CHINESE PHARMACEUTICAL UNIV (CN) | 2005-02-23 | — | — | CN | disclosed |
| US-5591722-A | ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0491793-A4 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | — | 1993-03-03 | — | — | EP | disclosed |
| EP-0491793-A1 | 2'-DEOXY-4'-THIORIBONUCLEOSIDES AS ANTIVIRAL AND ANTICANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142285-A1 | COSMETIC COMPOSITION COMPRISING ASCORBIC ACID 2-GLUCOSIDE AND ERGOTHIONEINE | OGG1, MPG, UNG | CRBN 4352/4885MMP2 707/4885TP53 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.